On Monday, Following U.S. Stocks were among the “Top Losers“: Raptor Pharmaceutical (RPTP), McDermott International (MDR), Hemispherx BioPharma, (HEB), W&T Offshore, (WTI)
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) promulgated that on March 9, 2015, the Compensation Committee of the Corporation’s Board of Directors approved grants of inducement stock options to purchase an aggregate of 152,867 shares of ordinary stock to six new employees and a grant of 10,714 Restricted Stock Units (RSUs) to one new employee, in each case, following the Corporation’s 2014 Employment Commencement Stock Incentive Plan. The plan was approved by the Board of Directors under Rule 5635(c)(4) of the NASDAQ Global Select Market for equity grants to induce new employees to enter into employment with the Corporation.
Raptor Pharmaceutical Corp. (NASDAQ:RPTP)’s shares dwindled -3.03%, and closed at $11.52. The stock volatility for the week is 4.92%, while for the month remained 5.78%. The company holds consensus target price of $19.25.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -0.83 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 30.80% and Annual EPS growth for the past 5 years is considered as 0.50%.
The mean recommendation of analysts for this stock is 2.60. (where 1=Buy, 5=Sale).
Raptor Pharmaceutical Corp. (RPTP), a biopharmaceutical corporation, focuses on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. The corporation offers PROCYSBI, a delayed-release capsule, which is used for the administration of nephropathic cystinosis in adults, in addition to in six years and older children in the United States, in the 28 member states of the European Union, Norway, Liechtenstein, and Iceland.
McDermott International (NYSE:MDR) disclosed that it has been awarded initial work for a noteworthy power supply system replacement contract by Saudi Aramco for the Marjan field, offshore Saudi Arabia. Work is predictable to be executed through the fourth quarter of 2016 and will be comprised of in McDermott’s first quarter 2015 backlog.
McDermott International (NYSE:MDR), declined -2.98%, and closed at $3.26. The company holds the market capitalization of 799.04M. For the last twelve months, the stock was able to keep return on equity at -5.20%, while return on assets at -2.20%, in response to its return on investment at -0.50%. Its 20-day moving average gained 12.05%, below 50-day moving average of 20.79%, above 200-day moving average of -35.53% from the latest market price of $3.26. The mean recommendation of analysts for this stock is 3.00. (where 1=Buy, 5=Sale).
McDermott International (MDR) works as an engineering, procurement, construction, and installation corporation worldwide. The corporation operates through three segments: Asia Pacific, Americas, and the Middle East.
Hemispherx BioPharma, Inc (NYSEMKT:HEB) stated that it has executed an contract with Emerge Health Pty Ltd. to seek approval of Ampligen, an experimental immunotherapeutic, for Chronic Fatigue Syndrome in Australia and New Zealand and to commence distribution of Ampligen in both countries on a named-patient basis, where deemed appropriate.
Hemispherx BioPharma, Inc (NYSEMKT:HEB), dipped -2.94%, and closed at $0.228. The company has the market capitalization of $51.20M. The beta value of the stock is 1.26. On the other hand the stock’s volatility for the week is 6.35%, and for the month is 7.29%. The stock’s price to book ratio is $1.63, however price to sale ratio is $247.94. Analyst’s mean recommendation regarding this stock is 2.00. (where 1=Buy, 5=Sale).
Hemispherx BioPharma, Inc (HEB) a specialty pharmaceutical corporation, is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States.
W&T Offshore, Inc. (NYSE:WTI) unveiled its year-end 2014 proved reserves, fourth quarter and full year 2014 operations and financial results, 2015 capital budget and drilling plans, and 2015 production and expense guidance. Some of the highlights comprise: Our proved reserves at year-end 2014 were 120 million barrels of oil equivalent (“Boe”) with a PV-10 value of $2.6 billion, not including the effect of estimated asset retirement obligations. Both the amount and value of our proved reserves have raised over the preceding year even with our continued focus on longer-term projects.
W&T Offshore, Inc. (NYSE:WTI), dropped -2.83%, and closed at $5.15. The stock has price to sale ratio of 0.41, however, price to book ratio is 0.77. With recent decline, the year-to-date (YTD) performance reflected a -30.69% decline below last year. During the past month the stock lose -21.37%, bringing three-month performance to -11.66% and six-month performance to -61.39%. The mean recommendation of analysts for this stock is 2.70. (where 1=Buy, 5=Sale).
W&T Offshore, Inc. (WTI) an independent oil and natural gas producer, together with its auxiliaries, engages in the attainment, exploration, and development of oil and natural gas properties primarily in the Gulf of Mexico and onshore in the Permian Basin of West Texas.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
